Merck sees promise in Macrophage Pharma
Merck Ventures has become the latest group to invest in Macrophage Pharma and take a position on the UK biotech’s board of directors. The venture capital arm of German drugmaker Merck is streaming new funds into the group equal to that already provided individually by existing investors the CRT Pioneer Fund (CPF), Novo Holdings A/S and Aglaia Biomedical Ventures BV.